Episode Details

Trump’s new tariff plan targets overseas generic drugs with 100% duties starting August 2028, escalating to 200% the next year, aiming to force pharma companies to reshore manufacturing to the U.S. While intended to boost domestic production and secure supply chains—especially critical given reliance on foreign ingredients from India and China—the move risks driving up drug prices, triggering shortages, or pushing companies out of the U.S. market. Experts warn that the high tariffs may not be the most effective strategy for reshoring, especially given the razor-thin margins in the generic drug industry. Still, the administration sees this as part of a broader push to bring manufacturing back home, using economic pressure as a lever across sectors to strengthen national security and consumer access.

Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/1f48a6f420b49750